Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies

PURPOSE: Sirolimus is the prototypical mammalian target of rapamycin inhibitor. Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including vascular endothelial receptor kinases (VEGFR). These agents have different mechanisms of action providing a strong rationale for combina...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Gangadhar, Tara C., Cohen, Ezra E. W., Wu, Kehua, Janisch, Linda, Geary, David, Kocherginsky, Masha, House, Larry K., Ramirez, Jackie, Undevia, Samir D., Maitland, Michael L., Fleming, Gini F., Ratain, Mark J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2011
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3077032/
https://ncbi.nlm.nih.gov/pubmed/21447721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2061
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन